NDAORALTABLET
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Codeine sulfate is an oral small-molecule opioid analgesic indicated for pain relief. It acts as a mu-opioid receptor agonist, with analgesic and antitussive properties. This generic formulation has been available since 2009 and serves patients requiring moderate pain management.
$0.241MPart D
LOE ApproachingDeclining lifecycle stage with minimal Medicare Part D penetration signals reduced team investment and limited career growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers minimal career growth potential; roles are largely operational and cost-focused rather than strategic or innovative. Working on a declining, low-revenue generic carries limited visibility and advancement opportunity within a pharmaceutical organization.
Generic Product ManagerRegulatory Affairs Specialist
Worked on CODEINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.